Category: clinical study retractions

Plagiarism charge bites authors of oral pain paper

jiohheader_imgThe Journal of International Oral Health has retracted a 2014 paper on dental pain by a group from India. Although the ostensible reason was plagiarism, we wonder if the offending authors might gone a bit further.

The article, “Sniffing out pain: An in vivo intranasal study of analgesic efficacy,” purported to be a study of 20 patients receiving different therapies for emergency oral pain. It has yet to be cited, according to Thomson Scientific’s Web of Knowledge. Here’s the abstract: Continue reading Plagiarism charge bites authors of oral pain paper

Retraction appears for social psychologist Jens Förster

forster-j-a1
Jens Förster

A retraction has appeared for Jens Förster, the former University of Amsterdam social psychologist whose work has come under serious scrutiny by two official committees.

Here’s the notice for 2012’s “Sense Creative! The Impact of Global and Local Vision, Hearing, Touching, Tasting and Smelling on Creative and Analytic Thought,” a paper which first appeared in Social Psychological and Personality Science:
Continue reading Retraction appears for social psychologist Jens Förster

“Conscious fabrication” leads to retraction of diabetes study

diabetcoverDiabetologia has retracted a 2011 meeting abstract from a group in Sweden, indicating that the second author has been found guilty of research misconduct — a charge the scientist denies.

The abstract, “Reduced syntaxin-5 in skeletal muscle of patients with type 2 diabetes is linked to increased diacylglycerol, activation of PKCtheta and impaired insulin signalling,” was presented at the annual meeting of the European Association of the Study of Diabetes. The first author was Kurt Højlund, who now is at the University of Southern Denmark. The second author was Pontus Boström, of the Karolinska Institutet.

According to the notice: Continue reading “Conscious fabrication” leads to retraction of diabetes study

Retraction appears for faked study of Novartis anti-cancer compound

Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.
Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.

A paper by a former postdoc at MD Anderson Cancer Center who “admitted to knowingly and intentionally falsifying” a figure has been retracted.

In August, the Office of Research Integrity announced that it had sanctioned Jun Fu for faking data in a study of the results of a mouse study of NVP-HSP990, a Novartis compound designed to fight brain tumors. Here’s the notice for the study in question, published in Cancer Research:
Continue reading Retraction appears for faked study of Novartis anti-cancer compound

Paper on circulating tumor cells taken out of circulation after lab error

medical oncologyA group of researchers at the Guangdong Academy of Medical Sciences in Guangzhou, China have retracted a paper that came out of a clinical trial on transarterial chemoembolization, a targeted kind of chemotherapy.

According to the notice, one of the authors mixed up the control samples with the clinical samples, and “could not recall which samples were in the wrong group.” The paper hasn’t yet been cited, according to Thomson Scientific’s Web of Knowledge.

Here’s the notice in Medical Oncology:

Continue reading Paper on circulating tumor cells taken out of circulation after lab error

Lancet journal puts ICU paper on watch after authors acknowledge potentially fatal flaw

lancetrmLancet Respiratory Medicine has issued an expression of concern for a meta-analysis on tracheostomy in the intensive care unit that they published earlier this year.

The paper, “Effect of early versus late or no tracheostomy on mortality of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis“, came from a group at Harvard, Weill Cornell and the University of Athens. The authors purported to find that: Continue reading Lancet journal puts ICU paper on watch after authors acknowledge potentially fatal flaw

“Significant” copying forces retraction of sternotomy paper

icatsInteractive Cardiovascular and Thoracic Surgery has yanked a 2005 sternotomy paper by a group of researchers who plagiarized from an earlier article on the subject.

The article, “The complications of repeat median sternotomy in paediatrics: six-months follow-up of consecutive cases,” came from a team at Glenfield Hospital in Leicester, England, and has been cited eight times, according to Scopus.

Here’s the notice:

Continue reading “Significant” copying forces retraction of sternotomy paper

“Know how to recognize pseudoscience:” Reader reveals how fish oil paper came to be retracted

Ian Garber
Ian Garber

After our post yesterday on a fishy retraction from author Brian Peskin, a reader who alerted the journal to problems got in touch to give us the lowdown.

Ian Garber is in the last year of medical residency at the University of British Columbia. Here’s the story he told us via email: Continue reading “Know how to recognize pseudoscience:” Reader reveals how fish oil paper came to be retracted

“Undeclared competing interest” sinks fish oil takedown by author fined for deceptive claims

Snake swallowing a whole fish
Image via Jesse Palmer

The Journal of Lipids has retracted an aggressively negative review article called “Why Fish Oil Fails,” written by one Brian S. Peskin, whose bogus health claims have landed him in plenty of hot water in the past.

Here’s the notice: Continue reading “Undeclared competing interest” sinks fish oil takedown by author fined for deceptive claims

“I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

douglas_melton
Doug Melton

Harvard stem cell researcher Doug Melton got a lot of press last year for research on a hormone he named betatrophin, after its supposed ability to increase production of beta cells, which regulate insulin.

Now, the conclusions from that paper, which has been cited 59 times, according to Thomson Scientific’s Web of Knowledge, have been called into question by research from an independent group, as well as follow-up work from the original team.

The interest was driven by the hormone’s potential as a new treatment for diabetes. In 2013, Melton told the Harvard Gazette that betatrophin could be in clinical trials within three to five years. Here’s Kerry Grens in The Scientist: Continue reading “I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers